secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001558370-23-014390
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA Q2 net loss $18M; HB-200 Phase 2 shows 43% ORR in HPV16+ head and neck cancer
--------------------------------------------------------------------------------

- Net loss $18.0M in Q2 2023 vs $16.4M in Q2 2022; revenue flat at $2.7M.
- Cash $136.0M at June 30, 2023, up from $113.4M at Dec 31, 2022, after $50M June offering.
- Phase 2 HB-200 + pembrolizumab: 43% ORR in CPI-naïve patients, double pembrolizumab alone; randomized trial planned H1 2024.
- R&D expenses rose $3.6M to $19.7M on higher clinical costs for HB-200, HB-300, and partnered programs.
- Exchange offer for 627,632 underwater options (exercise >$6.50) to eligible non-executive employees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837023014390/0001558370-23-014390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837023014390/hook-20230810x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer